Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agape ATP Co. stock logo
ATPC
Agape ATP
$1.57
+0.6%
$1.51
$0.90
$8.00
$78.51M-0.551.75 million shs85,307 shs
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
$7.41
-0.5%
$4.87
$3.80
$26.70
$32.17M-0.8424,664 shs52,715 shs
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
$2.22
+4.7%
$3.48
$2.10
$9.91
$83.61M0.99131,027 shs114,021 shs
Exagen Inc. stock logo
XGN
Exagen
$5.71
-7.3%
$4.54
$1.49
$7.20
$102.79M1.5108,667 shs357,579 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agape ATP Co. stock logo
ATPC
Agape ATP
+0.32%-20.71%+16.30%+23.62%-66.67%
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
-3.00%+11.09%+82.24%+45.87%+20.47%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
+4.72%-23.71%-35.84%-51.10%-76.13%
Exagen Inc. stock logo
XGN
Exagen
-7.31%-5.15%+29.77%+10.66%+307.86%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Agape ATP Co. stock logo
ATPC
Agape ATP
0.501 of 5 stars
0.03.00.00.03.80.00.0
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
0.4996 of 5 stars
0.03.00.00.01.01.70.6
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
0.9553 of 5 stars
0.04.00.00.02.42.50.0
Exagen Inc. stock logo
XGN
Exagen
4.3779 of 5 stars
3.53.00.04.52.43.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agape ATP Co. stock logo
ATPC
Agape ATP
0.00
N/AN/AN/A
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
0.00
N/AN/AN/A
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
0.00
N/AN/AN/A
Exagen Inc. stock logo
XGN
Exagen
3.00
Buy$7.5031.35% Upside

Current Analyst Ratings Breakdown

Latest CCM, XGN, SERA, and ATPC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2025
Exagen Inc. stock logo
XGN
Exagen
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/12/2025
Exagen Inc. stock logo
XGN
Exagen
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 5/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agape ATP Co. stock logo
ATPC
Agape ATP
$1.32M59.35N/AN/A$1.14 per share1.38
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
$383.96M0.08N/AN/A$56.67 per share0.13
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
$77K1,085.90N/AN/A$2.21 per share1.00
Exagen Inc. stock logo
XGN
Exagen
$56.72M1.81N/AN/A$1.33 per share4.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agape ATP Co. stock logo
ATPC
Agape ATP
-$2.10M-$0.73N/AN/A-194.09%-74.71%-56.08%5/13/2025 (Estimated)
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
-$41.93MN/A0.00N/AN/AN/AN/AN/A
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
-$36.24M-$0.94N/AN/AN/AN/A-51.73%-36.94%5/14/2025 (Estimated)
Exagen Inc. stock logo
XGN
Exagen
-$23.69M-$0.84N/AN/AN/A-30.36%-92.58%-33.74%5/12/2025 (Estimated)

Latest CCM, XGN, SERA, and ATPC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
-$0.24-$0.20+$0.04-$0.20$0.06 million$0.04 million
5/12/2025Q1 2025
Exagen Inc. stock logo
XGN
Exagen
-$0.20-$0.20N/A-$0.20$14.55 million$15.50 million
3/31/2025Q4 2024
Agape ATP Co. stock logo
ATPC
Agape ATP
N/A-$0.20N/A-$0.20N/A$0.36 million
3/19/2025Q4 2024
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
-$0.23-$0.25-$0.02-$0.25$0.01 million$0.02 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Agape ATP Co. stock logo
ATPC
Agape ATP
N/AN/AN/AN/AN/A
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
N/AN/AN/AN/AN/A
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
N/AN/AN/AN/AN/A
Exagen Inc. stock logo
XGN
Exagen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agape ATP Co. stock logo
ATPC
Agape ATP
0.05
3.59
3.53
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
1.15
0.47
0.46
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
N/A
2.11
2.11
Exagen Inc. stock logo
XGN
Exagen
1.54
4.05
4.05

Institutional Ownership

CompanyInstitutional Ownership
Agape ATP Co. stock logo
ATPC
Agape ATP
0.01%
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
N/A
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
54.64%
Exagen Inc. stock logo
XGN
Exagen
75.25%

Insider Ownership

CompanyInsider Ownership
Agape ATP Co. stock logo
ATPC
Agape ATP
9.67%
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
46.50%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
13.50%
Exagen Inc. stock logo
XGN
Exagen
26.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agape ATP Co. stock logo
ATPC
Agape ATP
4050.01 million3.60 millionNot Optionable
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
9704.34 million2.32 millionNot Optionable
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
12037.66 million28.44 millionOptionable
Exagen Inc. stock logo
XGN
Exagen
22018.00 million13.03 millionOptionable

Recent News About These Companies

William Blair Issues Negative Outlook for Exagen Earnings
Equities Analysts Set Expectations for Exagen Q1 Earnings
Exagen Inc. Prices Public Offering of Common Stock
KeyBanc maintains Exagen stock at Sector Weight
KeyBanc maintains Exagen stock at Sector Weight
Exagen Inc. stock logo
Exagen (XGN) Expected to Announce Earnings on Monday

New MarketBeat Followers Over Time

Media Sentiment Over Time

Agape ATP stock logo

Agape ATP NASDAQ:ATPC

$1.57 +0.01 (+0.64%)
As of 05/9/2025 03:58 PM Eastern

Agape ATP Corporation, an investment holding company, supplies health and wellness products and health solution advisory services in Malaysia. It offers four series of programs that consist of various services and products under the ATP Zeta Health Program, ÉNERGÉTIQUE, BEAUNIQUE, and E.A.T.S. names. The company's products include ATP1s Survivor Select that contains various essential nutrients required by the human body to maintain normal metabolism; ATP3 Ionized Cal-Mag, a calcium and magnesium minerals supplement; ATP4 Omega Blend, an oil blend that provides a bio-effective balance of essential fatty acids, omega 3, and omega 6; ATP5 BetaMaxx, a natural immune enhancer; AGN-Vege Fruit Fiber, a nutrition-based formulation for intestines and stomach; AGP1-Iron to improve iron deficiency anemia; and YFA-Young Formula, an anti-aging and youthful maintenance supplement. It also provides BEAUNIQUE brand products comprising Mito+, an antioxidant drink for cellular, immune, metabolic, brain, and skin health; and Trim+, which inhibits the activities of carbohydrates digestive enzymes that result in a reduction of the breakdown and absorption of sugars. In addition, the company offers energy masks, including N°1 Med-Hydration, N°2 Med-Whitening, and N°3 Med-Firming, as well as hyaluronic acid serum and mousse facial cleanser under ÉNERGÉTIQUE brand; and soy protein isolate powder, and an antioxidant under Livo5 brand name. Further, it sells health and wellness products; and promotes wellness and wellbeing lifestyle through online editorials, programs, events, and campaigns, as well as provides health therapies. The company was incorporated in 2016 and is headquartered in Kuala Lumpur, Malaysia.

Concord Medical Services stock logo

Concord Medical Services NYSE:CCM

$7.41 -0.04 (-0.54%)
As of 05/9/2025 03:55 PM Eastern

Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.

Sera Prognostics stock logo

Sera Prognostics NASDAQ:SERA

$2.22 +0.10 (+4.72%)
As of 05/9/2025 04:00 PM Eastern

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Exagen stock logo

Exagen NASDAQ:XGN

$5.71 -0.45 (-7.31%)
As of 05/9/2025 04:00 PM Eastern

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.